A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/40 (2006.01) A61K 31/00 (2006.01) A61K 31/395 (2006.01) A61K 31/407 (2006.01) A61K 41/00 (2006.01)
Patent
CA 2253613
A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)- 3,4-[N, N'-1,1'-((2"-ethoxy)-3"'(O)-4"'-(N,N-dimethylamino)-butane)-bis-(3,3'- indolyl)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
Méthode pour inhiber la croissance cellulaire endothéliale stimulée par le VEGF, telle qu'elle se manifeste dans la dégénérescence maculaire, et la perméabilité des capillaires stimulée par le VEGF, telle qu'on la constate dans l'oedème maculaire, au moyen en particulier de l'inhibiteur sélectif de l'isozyme de la PKC: chlorhydrate de (S)-3,4-[N, N'-1,1'-((2''-éthoxy)-3'''(O)-4'''-(N,N-diméthylamino)-butane)-bis-(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione.
Aiello Lloyd P.
Jirousek Michael R.
King George L.
Vignati Louis
Ways Douglas Kirk
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
Therapeutic treatment for vegf related occular diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic treatment for vegf related occular diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatment for vegf related occular diseases will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2020868